newsfilter
← Earnings
Earnings Releases·

Eloxx Pharmaceuticals — Third Quarter 2026 Earnings Summary

  • Net loss widened to $5.5 million ($0.49/share) for Q3 2026 from $0.4 million ($0.58/share) in Q3 2025, driven by $4.0 million in R&D expenses for the Phase 2b EXACT study and increased G&A costs.
  • Cash and cash equivalents decreased to $56.3 million as of September 30, 2026, from $62.0 million in June 2026, though management projects sufficient funds to operate into 2028.
  • Clinical progress includes dosing the first two patients in the Phase 2b EXACT study (NMAS) and finalizing the protocol for the Phase 2 EXPRESS study (nmADPKD), with top-line data expected mid-2027 and 2029 respectively.
  • Strategic updates include the appointment of T.R. Srinivas, M.D., as Chief Medical Officer and Geno Germano to the Board, alongside FDA feedback suggesting potential Breakthrough Therapy Designation eligibility for exaluren based on future structural and functional data.
Company
ELOXX PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology